Morgan Stanley Maintains Equal-Weight on Cytek Biosciences, Lowers Price Target to $18
Morgan Stanley maintains Cytek Biosciences (NASDAQ:CTKB) with a Equal-Weight and lowers the price target from $27 to $18.
Cytek Biosciences Q3 EPS $0.02, Inline, Sales $34.40M Beat $33.39M Estimate
Cytek Biosciences (NASDAQ:CTKB) reported quarterly earnings of $0.02 per share which met the analyst consensus estimate. The company reported quarterly sales of $34.40 million which beat the analyst consensus estimate
Earnings Scheduled For November 8, 2021
Companies Reporting Before The Bell
• Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million.
Cytek Biosciences Highlights Introduction Of New 25-Color Immunoprofiling Assay
The field of medical research has a new tool to develop vaccines, personal immunotherapies, and cures for cancer and other infectious diseases using Full Spectrum Profiling™ (FSP™) technology. Cytek
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 15)
Cytek Biosciences Says On Aug. 25 Entered Into Supply Agreement With Coherent; Coherent To Sell, Supply To Co Laser Products
On August 25, 2021, Cytek Biosciences, Inc. and Cytek (Wuxi) Biosciences Co., Ltd, a China subsidiary of Cytek Biosciences, Inc. (together, “Cytek”) entered into a Supply Agreement (the
Cowen & Co. Initiates Coverage On Cytek Biosciences with Outperform Rating
Cowen & Co. analyst Max Masucci initiates coverage on Cytek Biosciences (NASDAQ:CTKB) with a Outperform rating.